ADAM20: A Promising Drug Target and Biomarker for Hepatic Fibrosis

Target Name: ADAM20

NCBI ID: G8748

ADAM20

Other Name(s): ADAM metallopeptidase domain 20 | ADA20_HUMAN | ADAM 20 | a disintegrin and metalloproteinase domain 20 | Disintegrin and metalloproteinase domain-containing protein 20 preproprotein | disintegrin and metalloproteinase domain-containing protein 20 | Disintegrin and metalloproteinase domain-containing protein 20

ADAM20: A Promising Drug Target and Biomarker for Hepatic Fibrosis

Introduction

Fibrosis is a pathological process that involves the gradual accumulation of extracellular matrix (ECM) components, leading to the dysfunction and failure of tissues. Hepatic fibrosis, in particular, is a significant public health issue due to its high prevalence and serious consequences, including liver cirrhosis and liver failure. The development of new therapeutic approaches to treat fibrosis is crucial for improving patient outcomes. ADAM20, a protein known as ADAM20 (ADAM metallopeptidase domain 20), has emerged as a promising drug target and biomarker for hepatic fibrosis. This article will provide an overview of ADAM20, its functions in fibrosis, and its potential as a drug target.

Overview of ADAM20

ADAM20 is a 21-kDa protein that is expressed in a variety of tissues, including liver, heart, and kidneys. It is a member of the ADAM (A disintegrating collagen-remodeling) family, which includes ADAM1 (ADAM1), ADAM2 (ADAM2 ), ADAM3 (ADAM3), and ADAM4 (ADAM4). These proteins are involved in the degradation of extracellular matrix components and have been implicated in fibrosis, cancer, and other diseases.

ADAM20 is composed of a 21-kDa catalytic domain and a 155-kDa non-catalytic domain. The catalytic domain is responsible for the protein's unique catalytic activity, allowing it to hydrolyze the cross-linking bonds between collagen fibers, a key component of ECM , leading to the dissolution of the ECM and the formation of a disintegrating collagen network.

ADAM20's functions in fibrosis

The accumulation of ECM components, such as collagen, in tissues can contribute to fibrosis. Fibrotic tissue can be tolerated by a variety of pathological factors, including chronic mechanical stress, inflammation, and metabolic changes. ADAM20, in its role as a collagen degrader , may play a crucial role in the regulation of fibrotic tissue.

In animal models of fibrosis, ADAM20 has been shown to be involved in the degradation of collagen and the formation of a disintegrating collagen network. This is associated with the inhibition of matrix-remodeling activities of ADAM20, such as the ability to stimulate the production of extracellular matrix proteins.

In addition to its role in fibrosis, ADAM20 has also been shown to have anti-inflammatory effects. Fibrotic tissue is often characterized by an imbalance of pro-inflammatory and anti-inflammatory processes. ADAM20 has been shown to regulate the production of pro-inflammatory cytokines and to promote the production of anti-inflammatory cytokines, such as IL-10.

ADAM20's potential as a drug target

The potential of ADAM20 as a drug target is based on its unique functions in fibrosis and its involvement in the production of pro-inflammatory cytokines. Several studies have investigated the effects of ADAM20 inhibitors on fibrosis and have shown that these compounds can be effective in treating fibrotic diseases, including liver cirrhosis, heart failure, and cancer.

One of the most promising strategies for the treatment of fibrosis is the use of small molecules that can inhibit the activity of ADAM20. Several inhibitors, including API-007-0222 and compounds derived from natural products, have been shown to inhibit the activity of ADAM20 and to reduce the production of pro-inflammatory cytokines in fibrotic tissue.

Another approach to the treatment of fibrosis is the use of monoclonal antibodies (mAbs), which are laboratory-produced versions of antibodies that can be directed against specific proteins. MAbs have been shown to be effective in targeting and inhibiting the activity of ADAM20 in

Protein Name: ADAM Metallopeptidase Domain 20

Functions: May be involved in sperm maturation and/or fertilization

The "ADAM20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAM20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets